The John Hancock Multimanager 2040 Lifetime Portfolio fund underperformed its benchmark for Q1 of 2025. Click here to read the full commentary.

An analyst from Axis Securities said that Strides Pharma Science has delivered a decisive breakout above the falling channel ...